Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052566 | 1.00 | LCK (0.43) | LCKGSK3BDYRK1ACA12CA1 | |
| SCHEMBL15091115 | 0.85 | CYP17A1 (0.39) | LCKGSK3BDYRK1ANPC1RECQL | |
| SCHEMBL29971093 | 0.85 | CYP17A1 (0.39) | LCKGSK3BDYRK1ANPC1RECQL | |
| SCHEMBL6469040 | 0.84 | LCK (0.46) | LCKGSK3BDYRK1ACA12CA1 | |
| SCHEMBL30065454 | 0.84 | ATR (0.42) | LCKGSK3BDYRK1ANPC1RECQL | |
| SCHEMBL1192179 | 0.84 | ATR (0.42) | LCKGSK3BDYRK1ANPC1RECQL | |
| SCHEMBL13506610 | 0.84 | AAK1 (0.40) | LCKGSK3BDYRK1ACA1NPC1 | |
| SCHEMBL1181120 | 0.82 | RAB9A (0.52) | LCKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29112878 | 0.81 | GSK3B (0.41) | LCKGSK3BDYRK1ACA12CA1 | |
| SCHEMBL31088073 | 0.79 | CCNT1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710232-B2 | Imidazole derivatives used as TAFIa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-1740569-B1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864979-A1 | Imidazole-derivatives as TAFAIa-inhibitors | Sanofi-Aventis Deutschland GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1740569-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105781-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | TFPI, TFPI2, SERPINC1 | LCK 2563/4885GSK3B 2516/4885DYRK1A 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.